ProCE Banner Activity

Final Survival Analysis of BELLINI: Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Venetoclax added to bortezomib/dexamethasone improved PFS in patients with relapsed/refractory multiple myeloma and t(11;14) but resulted in increased mortality in the overall patient population.

Released: December 14, 2021

Expiration: December 13, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation